Morningstar Investment Management LLC Makes New $1.32 Million Investment in Becton, Dickinson and Company $BDX

Key Points

• Morningstar Investment Management LLC has made a new investment of approximately $1.32 million in Becton, Dickinson and Company, purchasing 7,681 shares during the second quarter.
• Wall Street analysts have provided a consensus rating of "Hold" for Becton, Dickinson and Company, with a target price averaging $205.40.
• Becton, Dickinson and Company recently declared a quarterly dividend of $1.04 per share, translating to an annualized yield of 2.2%.

Morningstar Investment Management LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,681 shares of the medical instruments supplier's stock, valued at approximately $1,323,000.

A number of other large investors have also recently made changes to their positions in BDX. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $27,000. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $29,000. Cornerstone Planning Group LLC grew its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $31,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BDX shares. Weiss Ratings reissued a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler restated a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Trading Up 0.1%

NYSE BDX opened at $186.76 on Tuesday. The company has a fifty day moving average of $190.23 and a 200 day moving average of $185.45. The company has a market capitalization of $53.53 billion, a PE ratio of 33.59, a P/E/G ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,023 shares of company stock valued at $562,036. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.